Strata Skin Sciences, Inc. in brief
Strata Skin Sciences, Inc. is a listed company in the Medical Devices industry, based in Horsham, Pennsylvania, USA. It was founded in 1989. Its last known market value was $22 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $31 M and a net loss of $6 M. Its largest business segments by sales in 2025 were Dermatology Recurring Procedures (70%) and Dermatology Procedures Equipment (30%). By market, the largest shares of its 2025 sales came from USA (67%), China (11%) and Middle East (6%). Its shares trade under the symbol SSKN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Strata Skin Sciences, Inc.
Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
The company's flagship product, XTRAC, is a medical device that allows for a trained dermatologist to treat skin conditions like Vitiligo and Psoriasis with monochromatic UV Light. Following completion of a successful conformity assessment procedure, Strata Skin Sciences has also been granted CE Mark approval for sale of MelaFind in the European Union.
In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Strata Skin Sciences, Inc. timeline
- 1989
- 🏁Founded
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2005
- 🔔· approximateInitial public offering on Nasdaq
- 2010
- ✎Renamed Mela Sciences, Inc.Formerly Electro Optical Sciences Inc.
- 2016
- ✎Renamed STRATA Skin Sciences, Inc.Formerly Mela Sciences, Inc..
- 📈· approximateListed on Nasdaq as SSKN
- 2022
- 💰Record revenue of $36 millionFY2022, the highest of the 8 years on record.
Events of Strata Skin Sciences, Inc. from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,943 (Jan 2020) · #4,056 (Jan 2021) · #4,940 (Jan 2022) · #5,093 (Dec 2022) · #4,970 (Jul 2023) · #4,334 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -20.4%
- Operating margin
- -15.3%
- Return on equity
- -215.1%
- Liabilities / assets
- 90.5%
- Net debt
- $7M
- Revenue growth
- -8.5%
- R&D / revenue
- 1.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $31M | -8.5% | $-5M | $-6M | -20.4% |
| Dec 2024 | $34M | +0.6% | $-9M | $-10M | -30.1% |
| Dec 2023 | $33M | -7.7% | $-9M | $-11M | -32.5% |
| Dec 2022 | $36M | +20.6% | $-5M | $-6M | -15.3% |
| Dec 2021 | $30M | +29.8% | $-4M | $-3M | -9.0% |
| Dec 2020 | $23M | -26.9% | $-4M | $-4M | -19.1% |
| Dec 2019 | $32M | +5.8% | $-3M | $-4M | -12.0% |
| Dec 2018 | $30M | — | $-3M | $-4M | -13.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-3M | $1M | $-4M | $-1.35 | — |
| Dec 2024 | $0M | $2M | $-1M | $-2.65 | — |
| Dec 2023 | $-1M | $5M | $-6M | $-3.10 | — |
| Dec 2022 | $-1M | $4M | $-5M | $-0.16 | — |
| Dec 2021 | $2M | $4M | $-2M | — | — |
| Dec 2020 | $2M | $2M | $-0M | $-0.13 | — |
| Dec 2019 | $2M | $0M | $2M | $-0.11 | — |
| Dec 2018 | $3M | — | — | $-0.15 | — |
Quarterly results
Latest quarter to Dec 2025: revenue $9M (-2.8% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2025.
SEC filings
- Mar 26, 202610-KAnnual report · period to Dec 2025
- Feb 11, 20268-KCurrent reportListing notice · Other events
- Dec 17, 20258-KCurrent reportRegulation FD disclosure
- Dec 10, 20258-KCurrent reportShareholder vote
- Nov 14, 202510-QQuarterly report · period to Sep 2025
- Nov 13, 20258-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 30, 2025DEF 14AProxy statement
- Oct 16, 20258-KCurrent reportOther events
- Oct 14, 20258-KCurrent reportListing notice
- Sep 4, 20258-KCurrent reportRegulation FD disclosure
- Sep 3, 20258-KCurrent reportMaterial agreement · Regulation FD disclosure
- Aug 22, 20258-KCurrent reportListing notice
Official filings of Strata Skin Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $31 M
- Operating income
- $-5 M
- Net income
- $-6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $31 M
- Total liabilities
- $28 M
- Total equity
- $3 M
As of December-2025
Insider trading at Strata Skin Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Samuel RubinsteinDirector | Buy | +2,168 | $1.400 | $3 K | 5,934 | Form 4 |
| filed | Samuel RubinsteinDirector | Buy | +2,832 | $1.410 | $4 K | 8,766 | Form 4 |
| filed | Samuel RubinsteinDirector | Sell | -5,500 | $1.320 | $7 K | 12,360 | Form 4 |
| filed | Samuel RubinsteinDirector | Sell | -7,200 | $1.340 | $10 K | 5,160 | Form 4 |
| filed | Samuel RubinsteinDirector | Sell | -1,394 | $1.360 | $2 K | 3,766 | Form 4 |
| filed | Uri GeigerDirector, 10% owner | Buyindirect | +230,573 | $3.140 | — | 1.44 M | Form 4 |
| filed | Accelmed Growth Partners (AGP) Ltd10% owner | Buy | +230,573 | $3.140 | $724 K | 1.44 M | Form 4 |
| filed | Dolev RafaeliChief Executive Officer, Director | Buy | +19,100 | $3.140 | $60 K | 143,156 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Strata Skin Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5 reverse split ; 1-for-10 reverse split in the period to ; 1-for-10 reverse split
Trading halts
- 2025-08-27 19:22 UTC, code LUDP, resumed 19:27 UTC
Fails to deliver
- : 3 shares
- : 21 shares
- : 57 shares
- : 129 shares
- : 5 shares at $0.13
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Strata Skin Sciences, Inc. scorecard#
Passes 0 of the 15 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 6
- ✗Revenue grew in the newest year-8.5%Revenue down 8.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.3%-5.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.3%-5.3% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-1.35 vs -2.65Diluted EPS -1.35 in fiscal 2025 against -2.65 the year before (report's currency).
- ✗Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$4 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-15.3%-15.3% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-158.9%-158.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-15.3%-15.3% in fiscal 2025 against -12.9% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.6×Current ratio 0.58 at the end of fiscal 2025.
- ✗Debt below equity5.3×Debt to equity 5.27 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.2%Diluted shares up 22.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Strata Skin Sciences, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -15.3% | -8.2% | |
| Net margin | -20.4% | -10.4% | |
| Return on equity | -158.9% | -16.8% | |
| Revenue growth, 3 years a year | -5.3% | 10.8% | |
| Revenue growth | -8.5% | 10.4% | |
| Debt to equity | 5.27× | 0.64× |
5of 9on the Piotroski tests of financial strength
- Revenue fell 8.5% against the year before.
- Net loss of $6 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$4 million.
- The share count rose 22.2% in the year.
Strata Skin Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 31−8.5%100% | 34+0.6%100% | 33−7.8%100% | 36+20.6%100% | 30+29.8%100% | 23−26.9%100% | 32+5.8%100% | 30−6.0%100% | 32r31+3.4%100% | 31r32—100% | |
| Cost of revenue | 13−10.6%41.7% | 14r14−3.7%42.7% | 15+3.5%44.7% | 14+42.1%39.8% | 10+13.1%33.8% | 9.0−20.9%38.8% | 11−11.1%35.8% | 13−2.0%42.7% | 13r13+2.9%40.9% | 13—41.2% | |
| Gross profit | 18−7.0%58.3% | 19r19+4.1%57.3% | 18−15.2%55.3% | 22+9.7%60.2% | 20+40.4%66.2% | 14−30.3%61.2% | 20+18.4%64.2% | 17−8.8%57.3% | 19r18+3.8%59.1% | 18r19—58.8% | |
| Research and development | 0.4−52.3%1.4% | 0.9−33.0%2.6% | 1.3+28.0%3.9% | 1.0−28.2%2.8% | 1.4+12.6%4.8% | 1.3+27.1%5.5% | 1.0−5.9%3.2% | 1.1−37.8%3.6% | 1.7−11.3%5.4% | 1.9—6.3% | |
| Selling and marketing | 13+5.5%42.7% | 12r12−4.1%37.0% | 13−15.3%38.8% | 15+16.7%42.3% | 13+45.0%43.7% | 9.0−24.7%39.1% | 12+13.0%38.0% | 11−5.6%35.6% | 11−7.0%35.4% | 12r13—39.4% | |
| General and administrative | 10−6.5%33.2% | 11r11+3.7%32.5% | 11+4.2%31.5% | 10+3.9%27.9% | 9.7+23.0%32.4% | 7.9−23.1%34.2% | 10+16.9%32.5% | 8.8+15.5%29.4% | 7.6r7.4−0.4%23.9% | 7.6—24.9% | |
| Operating expenses | — | — | — | — | 24+33.2%80.9% | 18−21.8%78.9% | 23+13.7%73.7% | 20−0.4%68.6% | 21r20−5.1%64.7% | 22r23—70.6% | |
| Total costs and expenses | 23−20.7%73.6% | 28r28+5.2%84.8% | 27+2.5%81.1% | 26+8.9%73.1% | 24—80.9% | — | — | — | — | — | |
| Operating income | −4.7—−15.3% | −9.3—−27.6% | −8.6—−25.8% | −4.6—−12.9% | −4.4—−14.7% | −4.1—−17.7% | −3.0—−9.5% | −3.4—−11.2% | −1.8r−2.4—−5.7% | −3.6—−11.7% | |
| Interest and finance income | 0.4+69.4%1.3% | 0.2+4.8%0.7% | 0.2+160%0.7% | 0.1+493%0.2% | 0.0−90.0%0.1% | 0.2—0.6% | — | — | — | — | |
| Interest expense and finance costs | 2.0−7.0%6.4% | 2.1+28.5%6.3% | 1.6+77.1%4.9% | 0.9+195%2.6% | 0.3+48.8%1.0% | 0.2−59.0%0.9% | 0.5−54.9%1.6% | 1.1−64.3%3.8% | 3.2r4.6−34.8%10.1% | 4.9—16.0% | |
| Net interest income | — | — | — | — | — | −0.1—−0.3% | −0.5—−1.6% | — | — | — | |
| Other non-operating income (expense) | −1.5—−5.0% | −1.0—−3.0% | −2.3—−6.9% | −0.8−148%−2.3% | 1.7—5.8% | −0.1—−0.3% | −0.9—−2.9% | −0.9—−3.2% | −20r−16−3888%−61.7% | 0.5—1.7% | |
| Income before tax | −6.2—−20.4% | −10—−30.6% | −11—−32.7% | −5.5—−15.2% | −2.7—−8.9% | −4.1—−17.9% | −3.9—−12.5% | −4.3—−14.4% | −21r−19—−67.3% | −3.1—−10.0% | |
| Income tax | 0.0—0.0% | −0.2—−0.5% | −0.1−246%−0.3% | 0.1+85.3%0.2% | 0.0−87.6%0.1% | 0.3—1.2% | −0.1—−0.5% | −0.3−305%−0.9% | 0.1−49.4%0.4% | 0.3—0.8% | |
| Net income attributable to shareholders | −6.3—−20.4% | −10—−30.1% | −11—−32.5% | −5.5—−15.3% | −2.7—−9.0% | −4.4—−19.1% | −3.8—−12.0% | −4.0—−13.5% | −22r−19—−67.7% | −3.3—−10.9% | |
| Earnings per share, basic | -1.35—— | -2.65—— | -3.10r-0.31—— | -0.16—— | — | -0.13—— | -0.11—— | -0.15—— | -3.26r-2.85—— | -1.57r-0.31—— | |
| Earnings per share, diluted | -1.35—— | -2.65—— | -3.10r-0.31—— | -0.16—— | — | -0.13—— | -0.11—— | -0.15—— | -3.26r-2.85—— | -3.77r-0.75—— | |
| Shares, weighted average (basic) | 4.7+22.2%— | 3.8+9.0%— | 3.5r35−89.9%— | 35—— | — | 34+5.1%— | 32+63.2%— | 20+622%— | 2.7+28.1%— | 2.1r11—— | |
| Shares, weighted average (diluted) | 4.7+22.2%— | 3.8+9.0%— | 3.5r35−89.9%— | 35—— | — | 34+5.1%— | 32+63.2%— | 20+622%— | 2.7+17.2%— | 2.3r12—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.9+9.0%25.9% | 7.3+7.0%20.8% | 6.8+24.8%16.1% | 5.4−56.8%10.4% | 13+18.7%27.0% | 11+30.4%22.7% | 8.1−50.7%17.2% | 16+305%34.7% | 4.1+3.6%10.4% | 3.9—9.1% | |
| Receivables | 4.1−21.5%13.5% | 5.3+18.3%15.0% | 4.4−0.7%10.6% | 4.5+30.2%8.6% | 3.4+16.6%7.4% | 2.9−32.9%6.3% | 4.4+29.3%9.3% | 3.4+8.0%7.1% | 3.1−7.3%8.0% | 3.4—7.8% | |
| Inventory | 2.8+25.3%9.2% | 2.2−16.0%6.4% | 2.7−13.6%6.4% | 3.1r5.5−11.3%5.9% | 3.5+1.3%7.5% | 3.4+13.8%7.4% | 3.0+8.3%6.4% | 2.8−7.1%5.9% | 3.0+6.8%7.7% | 2.8—6.5% | |
| Other current assets | 0.8+50.3%2.5% | 0.5+60.6%1.4% | 0.3−54.8%0.7% | 0.7+49.6%1.3% | 0.5+39.6%1.0% | 0.3−35.5%0.7% | 0.5−4.3%1.1% | 0.5+0.6%1.1% | 0.5−13.6%1.4% | 0.6—1.4% | |
| Current assets | 16−6.0%51.1% | 17+6.8%47.5% | 16+3.3%37.0% | 15r18−24.6%28.8% | 20−19.6%42.9% | 25+5.4%53.1% | 24+1.5%49.8% | 23+116%48.9% | 110.0%27.5% | 11—24.9% | |
| Property, plant and equipment | 9.0−10.9%29.4% | 10−14.6%28.8% | 12+18.4%28.0% | 10.0r7.5+44.6%19.0% | 6.9+24.5%14.8% | 5.5+3.0%11.8% | 5.4+1.3%11.3% | 5.3−31.2%11.2% | 7.7−24.3%19.7% | 10—23.6% | |
| Right-of-use (leased) assets | 0.9−27.2%3.0% | 1.3+102%3.6% | 0.6−35.8%1.5% | 1.0+52.8%1.9% | 0.6−35.4%1.4% | 1.0−24.8%2.1% | 1.3—2.8% | 0—0.0% | — | — | |
| Goodwill | 1.40.0%4.7% | 1.4r2.7−78.1%4.1% | 6.5−25.9%15.5% | 8.80.0%16.8% | 8.80.0%18.9% | 8.80.0%18.8% | 8.80.0%18.6% | 8.80.0%18.5% | 8.80.0%22.5% | 8.8—20.4% | |
| Other intangible assets | 3.4−36.9%11.1% | 5.3−26.9%15.3% | 7.3−57.9%17.4% | 17+72.5%33.3% | 10+58.9%21.6% | 6.3−20.2%13.6% | 8.0−18.5%16.8% | 9.8−17.4%20.6% | 12r11−11.8%30.2% | 13r6.3—31.1% | |
| Total assets | 31−12.6%100% | 35r36−16.9%100% | 42−19.6%100% | 52+12.2%100% | 47−0.4%100% | 47−1.2%100% | 47−0.3%100% | 48+21.4%100% | 39r39−9.4%100% | 43—100% | |
| Accounts payable | 2.8+13.4%9.0% | 2.4−27.2%7.0% | 3.3−2.4%8.0% | 3.4+21.4%6.6% | 2.8+2.1%6.1% | 2.8+47.0%5.9% | 1.9+6.6%4.0% | 1.8−22.5%3.7% | 2.3+22.9%5.8% | 1.9—4.3% | |
| Debt due within a year | 15—50.3% | 0—0.0% | — | — | 0−100%0.0% | 1.5—3.2% | 0−100%0.0% | 0.3−89.4%0.5% | 2.4+39.3%6.1% | 1.7—4.0% | |
| Current liabilities | 27+99.6%87.6% | 13r15+10.0%38.4% | 12−9.3%29.0% | 13+4.9%25.7% | 13−32.0%27.5% | 19+8.1%40.3% | 17+102%36.8% | 8.6−17.7%18.1% | 10r7.7+15.8%26.8% | 9.0r6.1—20.9% | |
| Long-term debt | 0−100%0.0% | 15+1.0%43.5% | 15+101%35.8% | 7.5+2.1%14.3% | 7.3+597%15.7% | 1.1—2.2% | 0−100%0.0% | 7.1−9.0%15.0% | 7.9−19.5%20.1% | 9.8—22.6% | |
| Lease liabilities (non-current) | 0.7−25.1%2.3% | 0.9+288%2.6% | 0.2−61.1%0.6% | 0.6+55.6%1.2% | 0.4−44.8%0.8% | 0.7−34.1%1.5% | 1.1—2.3% | 0—0.0% | — | — | |
| Total liabilities | 28−7.8%90.5% | 30r31+2.1%85.8% | 29−3.7%69.8% | 30+43.7%58.2% | 21+1.4%45.5% | 21+11.7%44.6% | 19+15.0%39.5% | 16−15.5%34.2% | 19r16−31.6%49.2% | 28r28—65.2% | |
| Retained earnings | −254—−834% | −248—−710% | −238—−567% | −227—−435% | −222—−476% | −219—−468% | −215—−453% | −211—−444% | −204r−229—−521% | −182r−211—−422% | |
| Shareholders' equity | 2.9−41.5%9.5% | 5.0−60.8%14.2% | 13−41.9%30.2% | 22−14.1%41.8% | 25−1.8%54.5% | 26−9.6%55.4% | 29−8.3%60.5% | 31+57.2%65.8% | 20r22+32.2%50.8% | 15r15—34.8% | |
| Total liabilities and equity | 31−12.6%100% | 35r36−16.9%100% | 42−19.6%100% | 52+12.2%100% | 47−0.4%100% | 47−1.2%100% | 47−0.3%100% | 48+21.4%100% | 39r39−9.4%100% | 43—100% | |
| Shares outstanding | 5.9+41.2%— | 4.2+19.0%— | 3.5r35−89.9%— | 35+1.0%— | 34+1.7%— | 34+2.6%— | 33+10.0%— | 30+596%— | 4.3+98.6%— | 2.2r11—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 4.1−17.0%13.4% | 5.0−10.5%14.8% | 5.6+4.9%16.6% | 5.3r2.4+152%14.6% | 2.1+5.0%7.0% | 2.0r2.0−25.7%8.7% | 2.7−24.4%8.5% | 3.6−17.9%11.9% | 4.3−4.6%13.7% | 4.6—14.8% | |
| Share-based compensation | 0.6+50.6%2.1% | 0.4−67.2%1.3% | 1.3−11.1%3.9% | 1.5−10.8%4.1% | 1.6+0.6%5.5% | 1.6+36.7%7.1% | 1.2+32.2%3.8% | 0.9+386%3.0% | 0.2+64.6%0.6% | 0.1—0.4% | |
| Cash from operating activities | −2.8−1586%−9.1% | 0.2—0.6% | −0.5—−1.6% | −0.9r−1.1−161%−2.6% | 1.5−28.1%5.0% | 2.1−6.0%9.1% | 2.2−23.0%7.1% | 2.9−30.0%9.7% | 4.1+1186%13.0% | 0.3—1.0% | |
| Capital expenditure | −1.5—−4.8% | −1.6—−4.9% | −5.0—−15.0% | −3.7r−3.6—−10.3% | −3.7—−12.2% | −2.2r−0.0—−9.4% | −0.1—−0.4% | — | — | — | |
| Acquisitions, net of cash acquired | — | — | 0—0.0% | −0.6—−1.7% | −3.5—−11.6% | 0—0.0% | — | — | 0—0.0% | −0.1—−0.4% | |
| Cash from investing activities | −1.5—−4.8% | −1.6—−4.9% | −5.0—−15.0% | −4.4r−4.2—−12.1% | −7.1—−23.8% | −2.2—−9.4% | −2.8—−8.8% | −1.8—−6.0% | −2.2—−6.9% | −0.9—−2.8% | |
| Debt issued | — | 0−100%0.0% | 7.0—21.0% | 0−100%0.0% | 8.0+216%26.7% | 2.5—10.9% | — | — | 0−100%0.0% | 1.5—4.9% | |
| Debt repaid | — | — | — | 0—0.0% | −0.5—−1.7% | 0—0.0% | −7.6—−24.0% | −3.0—−10.0% | −1.4—−4.5% | 0—0.0% | |
| Shares issued | 3.6+84.2%11.7% | 1.9—5.8% | 0—0.0% | — | — | — | 0−100%0.0% | 17—56.9% | 0—0.0% | — | |
| Cash from financing activities | 3.6+85.9%11.7% | 1.9−71.9%5.7% | 6.9—20.6% | −0.5−643%−1.4% | 0.1−96.4%0.3% | 2.5—11.0% | −0.3−103%−0.9% | 11—37.9% | −1.8−254%−5.7% | 1.2—3.8% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | 0—0.0% | −0.0−150%−0.0% | 0.0—0.0% | |
| Change in cash | −0.7−243%−2.2% | 0.5−63.9%1.4% | 1.3—4.0% | −5.8—−16.0% | −5.5−323%−18.4% | 2.5—10.8% | −0.9−107%−2.7% | 12+8707%41.6% | 0.1−77.4%0.4% | 0.6—2.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 31, 2025 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 31−8.5%100% | 9.3*−3.0%100% | 6.9−21.2%100% | 7.7−9.2%100% | 6.8+0.9%100% | 9.6*+10.2%100% | 8.8−0.6%100% | 8.4+2.2%100% | 6.8−10.7%100% | 8.7*—100% | 8.9—100% | 8.3—100% | 7.6—100% | |
| Cost of revenue | 13−10.5%42.2% | 3.7*−3.5%39.6% | 2.7−21.8%39.6% | 3.4−2.9%43.8% | 3.2−13.9%46.5% | 3.8r3.8*−1.9%39.8% | 3.5r3.5−9.9%39.9% | 3.5r3.5−12.1%41.0% | 3.7+15.6%54.4% | 3.9*—44.7% | 3.9—44.0% | 3.9—47.7% | 3.2—42.0% | |
| Gross profit | 18−7.1%57.8% | 5.6*−2.6%60.4% | 4.2−20.8%60.4% | 4.3−13.5%56.2% | 3.6+18.4%53.5% | 5.8r5.8*+20.0%60.2% | 5.3r5.3+6.7%60.1% | 5.0r4.9+15.3%59.0% | 3.1−29.8%45.6% | 4.8*—55.3% | 5.0—56.0% | 4.3—52.3% | 4.4—58.0% | |
| Research and development | 0.4−52.3%1.4% | 0.1*−66.5%0.7% | 0.2−29.2%2.5% | 0.1−56.8%1.1% | 0.1−60.2%1.4% | 0.2*−47.4%2.1% | 0.2−2.0%2.8% | 0.2−46.8%2.4% | 0.2−23.5%3.6% | 0.4*—4.4% | 0.2—2.8% | 0.4—4.5% | 0.3—4.2% | |
| Selling and marketing | 13+5.4%42.3% | 3.3*+1.2%35.0% | 3.2+5.7%46.2% | 3.5+15.7%46.1% | 3.0−0.8%43.9% | 3.2r3.2*+16.5%33.6% | 3.0r3.0−0.4%34.4% | 3.1r3.0−10.6%36.2% | 3.0−19.3%44.7% | 2.8*—31.8% | 3.0—34.3% | 3.4—41.4% | 3.7—49.5% | |
| General and administrative | 10−6.5%33.2% | 2.3*−4.6%24.3% | 2.7−26.3%38.5% | 3.0r2.9+36.1%39.1% | 2.3r2.6−16.4%33.2% | 2.4r2.7*−16.1%24.7% | 3.6r3.7+58.6%41.2% | 2.2r2.2−11.6%26.1% | 2.7r2.7−7.2%40.1% | 2.8*—32.4% | 2.3—25.8% | 2.5—30.2% | 2.9—38.5% | |
| Total costs and expenses | 23−20.7%73.6% | 5.1*−49.0%55.2% | 5.4−22.3%77.3% | 6.6r6.5+21.3%86.3% | 5.5r5.7−9.9%80.5% | 10r10.0*+21.9%105% | 6.9r7.0+23.7%78.3% | 5.5r5.4−13.1%64.7% | 6.1r6.0−12.8%90.1% | 8.2*—94.9% | 5.6—62.9% | 6.3—76.1% | 7.0—92.2% | |
| Operating income | −4.7—−15.3% | 0.5*—5.3% | −1.2—−16.9% | −2.3r−2.2—−30.1% | −1.7r−2.0—−25.0% | −4.3r−4.2*—−44.7% | −1.6r−1.7—−18.2% | −0.5r−0.5—−5.7% | −2.9r−2.9—−42.7% | −3.4*—−39.6% | −0.6—−6.9% | −2.0—−23.8% | −2.6—−34.2% | |
| Interest and finance income | 0.4+69.4%1.3% | 0.1*−12.0%0.7% | 0.0−27.9%0.7% | 0.2+319%2.9% | 0.1+53.3%1.0% | 0.1*−9.6%0.8% | 0.1−24.4%0.8% | 0.1+157%0.6% | 0.0+21.6%0.7% | 0.1*—1.0% | 0.1—1.0% | 0.0—0.3% | 0.0—0.5% | |
| Interest expense and finance costs | 2.0−7.0%6.4% | 0.5*−6.0%5.2% | 0.5−7.3%7.2% | 0.5−7.5%6.4% | 0.5−7.3%7.1% | 0.5*−2.5%5.4% | 0.5+1.7%6.1% | 0.5+78.2%6.3% | 0.5+83.2%7.8% | 0.5*—6.1% | 0.5—6.0% | 0.3—3.6% | 0.3—3.8% | |
| Other non-operating income (expense) | −1.5—−5.0% | −0.4*—−4.5% | −0.4—−6.5% | −0.3−168%−3.5% | −0.4—−6.1% | −0.4*—−4.6% | −0.5—−5.3% | 0.4—4.6% | −0.5—−7.1% | −0.4*—−5.1% | −0.4—−4.9% | −1.2—−14.4% | −0.2—−3.3% | |
| Income tax | 0.0—0.0% | 0.0*—0.1% | 0—0.0% | 0—0.0% | 0—0.0% | −0.2*—−1.8% | 0—0.0% | 0—0.0% | 0—0.0% | −0.1*—−1.1% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −6.3—−20.4% | 0.1*—0.6% | −1.6—−23.4% | −2.6r−2.5—−33.6% | −2.1r−2.4—−31.2% | −4.6r−4.5*—−47.6% | −2.1r−2.1—−23.6% | −0.1r−0.1—−1.1% | −3.4r−3.4—−49.8% | −3.8*—−43.7% | −1.1—−11.9% | −3.1—−38.2% | −2.8—−37.5% | |
| Earnings per share, basic | — | — | -0.36—— | -0.62r-0.60—— | -0.51r-0.58—— | — | -0.51r-0.53—— | -0.03—— | -0.10r-0.10—— | — | -0.30r-0.03—— | -0.90r-0.09—— | -0.08—— | |
| Earnings per share, diluted | — | — | -0.36—— | -0.62r-0.60—— | -0.51r-0.58—— | — | -0.51r-0.53—— | -0.03—— | -0.10r-0.10—— | — | -0.30r-0.03—— | -0.90r-0.09—— | -0.08—— | |
| Shares, weighted average (basic) | — | — | 4.5+11.0%— | 4.2+19.0%— | 4.2+19.0%— | — | 4.0+15.7%— | 3.5+0.5%— | 3.5r35−89.9%— | — | 3.5r35—— | 3.5r35—— | 35—— | |
| Shares, weighted average (diluted) | — | — | 4.5+11.0%— | 4.2+19.0%— | 4.2+19.0%— | — | 4.0+15.7%— | 3.5+0.5%— | 3.5r35−89.9%— | — | 3.5r35—— | 3.5r35—— | 35—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7.9—25.9% | 7.9+9.0%25.9% | 7.1+0.2%23.0% | 6.0+8.8%20.2% | 6.5+24.3%19.7% | 7.3+7.0%20.8% | 7.1−1.0%17.9% | 5.5−39.3%14.1% | 5.2+85.4%13.4% | 6.8—16.1% | 7.1—15.1% | 9.0—16.4% | 2.8—5.8% | |
| Receivables | 4.1—13.5% | 4.1−21.5%13.5% | 3.5−21.1%11.4% | 4.0+1.1%13.6% | 5.0+37.9%15.2% | 5.3+18.3%15.0% | 4.4−7.5%11.3% | 4.0−9.6%10.3% | 3.6−7.9%9.3% | 4.4—10.6% | 4.8—10.2% | 4.4—8.0% | 3.9—8.0% | |
| Inventory | 2.8—9.2% | 2.8+25.3%9.2% | 3.1+11.4%10.0% | 3.2+20.2%11.0% | 2.7−1.3%8.0% | 2.2−16.0%6.4% | 2.7−55.2%7.0% | 2.7−54.5%6.9% | 2.7−52.7%6.9% | 2.7—6.4% | 6.1—13.0% | 5.9—10.7% | 5.7—11.6% | |
| Other current assets | 0.8—2.5% | 0.8+50.3%2.5% | 0.6+113%2.1% | 0.6+63.2%1.9% | 0.4+6.1%1.1% | 0.5+60.6%1.4% | 0.3−10.0%0.8% | 0.3−36.2%0.9% | 0.3−50.4%0.9% | 0.3—0.7% | 0.3—0.7% | 0.5—1.0% | 0.7—1.4% | |
| Current assets | 16—51.1% | 16−6.0%51.1% | 14−10.1%46.5% | 14−0.4%46.7% | 16+19.9%48.1% | 17+6.8%47.5% | 16−19.5%40.3% | 14−34.9%35.7% | 13−8.8%33.8% | 16—37.0% | 20—41.8% | 21—38.5% | 15—29.5% | |
| Property, plant and equipment | 9.0—29.4% | 9.0−10.9%29.4% | 9.6−8.0%31.1% | 8.6−22.8%29.2% | 9.5−19.3%28.6% | 10−14.6%28.8% | 10+25.8%26.4% | 11+34.0%28.8% | 12+43.3%29.9% | 12—28.0% | 8.3—17.5% | 8.3—15.1% | 8.2—16.7% | |
| Right-of-use (leased) assets | 0.9—3.0% | 0.9−27.2%3.0% | 1.0−25.4%3.3% | 1.1−23.6%3.7% | 1.2−21.8%3.6% | 1.3+102%3.6% | 1.3+87.7%3.4% | 1.4+77.1%3.7% | 1.5+73.3%3.8% | 0.6—1.5% | 0.7—1.5% | 0.8—1.5% | 0.9—1.8% | |
| Goodwill | 1.4—4.7% | 1.40.0%4.7% | 1.4−74.9%4.7% | 1.4r2.7−74.9%4.8% | 1.4r2.7−74.9%4.3% | 1.4r2.7−78.1%4.1% | 5.7r6.5−35.3%14.5% | 5.7r6.5−35.3%14.7% | 5.7r6.5−35.3%14.5% | 6.5—15.5% | 8.8—18.7% | 8.8—15.9% | 8.8—17.9% | |
| Other intangible assets | 3.4—11.1% | 3.4−36.9%11.1% | 4.2−27.7%13.7% | 4.4−31.1%14.8% | 4.9−28.8%14.7% | 5.3−26.9%15.3% | 5.8−39.3%14.8% | 6.3−60.3%16.3% | 6.8−59.1%17.4% | 7.3—17.4% | 9.6—20.4% | 16—28.9% | 17—33.9% | |
| Total assets | 31—100% | 31−12.6%100% | 31−22.0%100% | 29r31−23.9%100% | 33r34−15.8%100% | 35r36−16.9%100% | 39r40−16.5%100% | 39r40−29.8%100% | 39r40−20.1%100% | 42—100% | 47—100% | 55—100% | 49—100% | |
| Accounts payable | 2.8—9.0% | 2.8+13.4%9.0% | 3.0+69.0%9.6% | 2.9+2.0%10.0% | 2.8−21.6%8.5% | 2.4−27.2%7.0% | 1.7−44.6%4.4% | 2.9−25.6%7.4% | 3.6+15.9%9.2% | 3.3—8.0% | 3.2—6.7% | 3.9—7.0% | 3.1—6.3% | |
| Debt due within a year | 15—50.3% | 15—50.3% | 1.9—6.1% | — | — | 0—0.0% | — | — | — | — | — | — | — | |
| Current liabilities | 27—87.6% | 27+99.6%87.6% | 15+14.2%48.9% | 13r14+11.1%42.6% | 14r15+15.6%41.2% | 13r15+10.0%38.4% | 13r14+9.5%33.4% | 11r12−20.0%29.2% | 12r13−9.9%30.0% | 12—29.0% | 12—25.5% | 14—25.6% | 13—26.6% | |
| Long-term debt | 0—0.0% | 0−100%0.0% | 13−11.3%43.7% | 15+1.0%51.8% | 15+1.0%46.1% | 15+1.0%43.5% | 15+0.9%38.5% | 15+0.8%39.0% | 15+101%38.4% | 15—35.8% | 15—31.8% | 15—27.1% | 7.5—15.3% | |
| Lease liabilities (non-current) | 0.7—2.3% | 0.7−25.1%2.3% | 0.7−26.5%2.4% | 0.8−28.0%2.6% | 0.8−28.4%2.5% | 0.9+288%2.6% | 1.0+255%2.5% | 1.1+180%2.8% | 1.2+138%3.0% | 0.2—0.6% | 0.3—0.6% | 0.4—0.7% | 0.5—1.0% | |
| Total liabilities | 28—90.5% | 28−7.8%90.5% | 29−1.9%95.7% | 29r30−1.0%98.2% | 30r32+0.9%91.0% | 30r31+2.1%85.8% | 30r31−3.3%76.1% | 29r30−23.6%75.5% | 30r31−0.0%75.9% | 29—69.8% | 31—65.7% | 38—69.4% | 30—60.7% | |
| Retained earnings | −254—−834% | −254—−834% | −254—−828% | −253r−253—−857% | −250r−251—−758% | −248—−710% | −244r−244—−619% | −242r−242—−623% | −241r−241—−615% | −238—−567% | −234—−496% | −233—−422% | −230—−468% | |
| Shareholders' equity | 2.9—9.5% | 2.9−41.5%9.5% | 1.3−86.0%4.3% | 0.5r0.3−94.4%1.8% | 3.0r2.7−68.4%9.0% | 5.0−60.8%14.2% | 9.4r9.3−41.9%23.9% | 9.5r9.5−43.8%24.5% | 9.4r9.4−51.2%24.1% | 13—30.2% | 16—34.3% | 17—30.6% | 19—39.3% | |
| Total liabilities and equity | 31—100% | 31−12.6%100% | 31−22.0%100% | 29r31−23.9%100% | 33r34−15.8%100% | 35r36−16.9%100% | 39r40−16.5%100% | 39r40−29.8%100% | 39r40−20.1%100% | 42—100% | 47—100% | 55—100% | 49—100% | |
| Shares outstanding | 5.9—— | 5.9+41.2%— | 5.3+26.3%— | 4.2+19.0%— | 4.2−88.1%— | 4.2+19.0%— | 4.2−88.1%— | 3.5−89.9%— | 35+0.5%— | 3.5r35—— | 35—— | 35—— | 35—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 4.1−17.0%13.4% | 0.8*−33.3%8.8% | 0.9−30.3%12.5% | 1.2−2.6%15.9% | 1.2−2.3%17.9% | 1.2*−3.8%12.8% | 1.2−14.5%14.1% | 1.3−12.5%14.8% | 1.2−10.6%18.5% | 1.3*—14.7% | 1.4—16.4% | 1.4—17.3% | 1.4r0.7—18.5% | |
| Share-based compensation | 0.6+50.6%2.1% | 0.2*+38.1%1.9% | 0.2+715%3.1% | 0.1−21.5%1.7% | 0.1+15.2%1.9% | 0.1*−56.4%1.3% | 0.0−92.3%0.3% | 0.2−53.7%1.9% | 0.1−65.5%1.7% | 0.3*—3.3% | 0.3—3.8% | 0.4—4.3% | 0.3—4.3% | |
| Cash from operating activities | −2.8−1586%−9.1% | −0.2*−134%−2.6% | −0.1*—−0.9% | −1.9*−428%−25.3% | −0.6—−8.1% | 0.7*−48.7%7.3% | −0.3*—−3.4% | 0.6*−37.6%7.0% | −0.8—−11.9% | 1.4r1.5*—15.8% | −2.0r−1.0*—−22.8% | 0.9r0.2*—11.5% | −0.8r−1.2—−10.8% | |
| Capital expenditure | — | −0.3*—−3.4% | −1.0*—−14.7% | — | −0.2—−2.9% | −0.5*—−5.3% | −0.1*—−0.7% | −0.3*—−4.1% | −0.7—−10.7% | −1.7r−1.9*—−19.8% | — | −1.7r−0.9*—−20.6% | −1.8r−1.4—−23.7% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | |
| Cash from investing activities | −1.5—−4.8% | −0.3*—−3.4% | −1.0*—−14.7% | 0.1*—0.8% | −0.2—−2.9% | −0.5*—−5.3% | −0.1*−132%−0.7% | −0.3*—−4.1% | −0.7—−10.7% | −1.7r−1.9*—−19.8% | 0.2r−0.8*—2.2% | −1.7r−0.9*—−20.6% | −1.8r−1.4—−23.7% | |
| Debt issued | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | |
| Shares issued | — | 1.4*—14.9% | — | — | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | — | |
| Cash from financing activities | 3.6+85.9%11.7% | 1.4*—14.9% | 2.2*+12.8%31.6% | 0*—0.0% | 0—0.0% | 0*—0.0% | 1.9*—22.1% | 0*−100%0.0% | −0.0—−0.3% | 0*—0.0% | −0.1*—−1.2% | 7.0*—84.4% | 0—0.0% | |
| Change in cash | −0.7−243%−2.2% | 0.8*+320%9.0% | 1.1*−29.7%16.0% | −1.9*−864%−24.5% | −0.7—−11.0% | 0.2*—2.1% | 1.6*—17.9% | 0.2*−96.0%2.9% | −1.5—−22.9% | −0.3*—−4.0% | −1.9*—−21.8% | 6.2*—75.3% | −2.6—−34.5% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Strata Skin Sciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Dermatology Recurring Procedures$21 M70%+1.5%
- Dermatology Procedures Equipment$9 M30%-26%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Strata Skin Sciences, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Strata Skin Sciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2024Chief executive | $601 K | $133 K | $297 K | $20 |
| 2023Chief executive | $1.0 M | $840 K | $693 K | $37 |
| 2022Mr. Robert Moccia | $983 K | −$194 K | $642 K | $53 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024
Events at Strata Skin Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Auditor changed 1 · Directors and officers 1 · Material agreement 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Feb 11, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2018 | $17 M | Private placement after listing | $10 to $50 million | — | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Product recalls by Strata Skin Sciences, Inc.#
1 recalls since 2015, 1,000 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| XTRAC Excimer Laser, Model No. AL8000, AL10000 The intended use is targeted UVB phototherapy for treatment of the skin conditions including psoriasis, vitiligo, atopic dermatitis, and leukoderma.When the Liquid Guide ( LLG) is not used according to the operator manual, the switch control wires may become loose and shorted. Shorted wires may lead to unintentional laser firing.Medical devicesClass II | 1,000 | Z-1455-2017 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Strata Skin Sciences, Inc. compares in Medical Devices
- Revenue$31 M · higher than 23% of 155
- Net margin-20.4% · higher than 36% of 144
- Revenue growth-8.5% · higher than 9% of 104
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Strata Skin Sciences, Inc.🇺🇸 | $22 M | — | -20.4% | -8.5% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Abbott Laboratories$181.1 B
- Medtronic plc$121.2 B
- Stryker Corporation$116.5 B
- Boston Scientific Corporation$66.2 B
- Edwards Lifesciences Corporation$52.8 B
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.$27.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Strata Skin Sciences, Inc.? Verify and update this profile — free
Show Strata Skin Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.